performance demonstrates Echoing our as another profile out growth comments, quarter which Thanks, Tom. planned. strategy, playing BDXXXX our QX, durable we in reliable, of delivered Tom’s strong consistent, in
COVID-driven several organic. quarter, So at for base fee X.X% first, performance. or underlying sciences, when strategic of business $X.X licensing the comparisons. in delivering more growth see adjusting revenue our exceeded comparison X% mid-single-digits billion beginning for the life product expectations organic and We with in We revenue our with growth exits,
almost in strong performance introductions is from Sciences impact revenue Total revenues which China testing mid-single-digit with $XXX Asia growth declined as in company million X% business BDB. growth well revenues growth. and the Medical base research Interventional which approximately basis were revenue BDI Pacific. in EMEA licensing of impacted that by was COVID-only of last growth Base $XX COVID BD new solutions BD million, Life Revenues was restrictions, in year. declined product expected, Base U.S., with in reflects and XXX comparison and strong growth BD regionally the to across reflects points. X.X% by from growth the slightly, strong offset
in year, near double-digit the deliver to growth continue full we to China. expect For
increasing our in durable an Our pipeline transformative base business by and portfolio, core continues acquisitions. revenue supported innovation from tuck-in solutions and performance be our contribution to the
to We anniversaried, basis organic continue which acquisitions XX from contribution we quarter. benefit about the in points also from the was
in Management into Further in in decline Medication some found be than X.X%. growing provide quarter, detail performance Systems, and Solutions Pharm in BD high-level and insight which now revenue Delivery announcement can me presentation. today’s Medication BD strong quarter. $X.X reflects growth each billion in Medical Medical segment’s the Solutions. Let totaled a earnings more the performance offset both
in The planned exits. the of well restrictions driven decline impact by as in MDS of China was COVID-related portfolio recent and as COVID strategic comparisons X%
with Access Double-digit demand driven our Vascular and growth in customer by both continue the performance and response of outside see XX.X% been We’ve strong to We Parata Rowa. was performance the automation solutions, in of MMS U.S. pleased Management strong very Parata. including pharmacy for
by As set driven and comparison growth the in dispensing prior MMS utilization also installations year higher expected, reflects to the dynamics. infusion COVID in
by which double-digit continued have Pyxis to Pharm in penetration of reflects portfolio. continue vaccine driven customer backlog XX.X%, strength our despite management orders connected biologic QX of year, very delivered and quarter for of high-growth of of growth BD a And HealthSight, We Systems growth healthy medication and in markets. another of strong XX% last the the
base in year-over-year licensing in of as quarter. COVID-only lower The revenue X.X%, and expanded growth underlying due BD decline billion is revenues. was by grew X.X% our testing base strong testing menu shortages driven over X.X% Growth the This Sciences discussed. Sciences the expected address licensing grow of comparison. was automation by through informatics laboratory of Solutions revenues molecular is Life to the X%, across and helping revenue driven over the installed or Life Integrated when mid-single-digit BD excluding labor leverage our to Diagnostic Kiestra $X.X continued excluding growth base. totaled previously BD Max that
in product by growth growth was strategy. combined was content and In portfolio of demand reagents, testing addition, orders. in by continued from differentiated strong strong reflects new partly with timing that aided X.X% for research double-digit Biosciences our there respiratory single-digit High dye enabled our launches the of growth
our We and for other as parameter flow higher to cancer of sorters demand and analyzers cytometry suite researchers conditions. continue do to cellular for continue expanded even immune-related see analysis
Interventional strong which by billion of was in acquisition comparison the advanced reconstruction to of and surgery continued of quarter, repair by double-digit Hernia, adoption BD growth the driven and coupled as growth portfolio which venous by relaunch, grew surgery performance the of chronic with by market strategic decline the and exits year Venovo tempered penetration PVD, Venclose, revenues Phasix, Growth Rotarex, BD driven addresses expected was the which by strong acquisition. a resorbable totaled then in scaffold and growing stocking. reflects in X.X%, planned X.X%. $X.X growth of Growth result ChloraPrep driven aided biosurgery, prior global Peripheral in in Tissuemed Intervention due XX.X%, double-digit tough dealer a continued insufficiency. to in reflects
constraints. reduced from to incontinence step drainage was solutions growth back with growth shore back performance an improved X.X% associated that release in and of prior supplier urological distributor in oncology, endourology in a Urology strong double-digit benefited chronic, our order stocking backlog the year. situation Asia Offsetting was to this prior supplier growth Greater to difficult comparison in performance. order due due and due reflects strong Additionally, within improved year PureWick,
diluted Now expectations. of EPS to which operating moving P&L. We our and that with gross our adjusted $X.XX, reported margin consistent of XX.X% of XX.X% QX margin included were
comparison QX from will breakout as is you While impact no year to in the providing half the of to of the decline year-over-year. longer specific testing higher are we weighted to prior the testing, expected driver a first in margins COVID-only margins recall the reported and is the
earlier as inflation that primarily was from driven selling materials included COVID margins Excluding shipping. raw margins The margins in that as basis through were as certain was around impacts peak business outsized elevated operating inventory in of base noted QX of XXXX, both of expected FY and XXX slightly such the to base our by inflation labor impact and as in improvement increases despite year-over-year. gross the well impacts in years, inflation up points both delivered
to portion to as strategic simplification of benefit lower-margin impact large our offset products from mitigation a the inflation and initiatives were able planned. and access portfolio this We of
expect move the impact Base to the we in as We revenues margin from through also year. inflation licensing impact includes the moderate growing from prior over performance the year.
through sales. benefited that was flow GP it as expected, As FX favorable recorded that in our had inventory we
support our of X.X% of of QX R&D aligned strategy to our timing of outlook. project investments reflects our innovation sales reflects growth spend. in long-term
QX to long-range the R&D elevated X%. year normalize remain around balance our expect We target over the and to in of of
items due certain tax was timing the in discrete anticipated during QX planned rate year. that were Our for of the than to lower
operations strategic rightsizing our impact cash December. and million cash WIP flows to optimize finished reflects $XXX quarter. December the We've customer product inflation delivery seen Operating progress from allocation; from approximately meet goods totaled approximately impact inventory [ph] and down our from and an reflects $XXX Regarding in good million raw on increase the investments dollars in of January The in and cash sequentially higher demand. January and flow balances. with of capital inventory materials
in purchases moderate to stability material strategic We raw markets. are as working improves select
However, we ensure where to results. customers make continue our delivering while trade-offs necessary support we to strong prudent
expect be Assuming the and towards down meeting $XXX to had positive a and approximately we our down cash long-term supply progress continued QX of source long-term chain, $XXX debt quarter with of balance of ratio the stabilization year and manage of million environment end to a and leverage a levels and net meaningful cash the conversion approximately goals. ended fiscal We million of times. paid macro in by the X inventory in continue this cash
and progresses deploy tuck-in our we M&A. increase can to cash, As towards the build cash year we capacity
to XXXX. our guidance Moving for fiscal
the our your be underlying assumptions detailed presentation. in can For also convenience, found our guidance
Given in first given goals, revenue execution FX revenue and the our increasing the strength rates. guidance, and reflecting EPS our of margin consistent base confident are performance, quarter our we latest our growth, of
Starting I key provide with some our guidance will insights of assumptions. into some revenues,
positioned and an guidance our our we the to X.XX% currency-neutral now increase of expect basis, in is X.XX% points at revenues our are driven well have restrictions growth This thus, are three First, strong guidance. and in or across our profile. our to prior X.XX% segments, durable grow above of which are XX the X.XX%. our base and growth we increasing to a consistent from China, for confidence QX is basis revenue we expectations outperformance impact by we of base despite On revenue initial delivering
Offsetting these for continue initiated increasing year, will full customers. of planned to efficiency that impact, of revenue our supply while our ensure actions we and growth contribution expect from predominant in products matter the expect and a this and guidance margin. recent revenue benefit positive most of with revenue base of basis Parata that approximately continues continue include the strategic driver. the base points capacity the reliable accretive full being approximately to XXX to XXX basis to impact to Our to the year We points manufacturing the QX portfolio exits being enable acquisitions
across strong providing planned are guidance, aren't long-term track deliver segment-specific fiscal in performance our we year, commitments. we to our While with this on line segments
be strong which to segment acquisition be company Parata; the includes Interventional midpoint. and given Sciences to total the growth Medical below comps the expect above Life range, growth We prior be year to of above
million $XXX to assuming the by versus about respiratory million testing, we market volumes shift $XX driven million is and expectation combination illness. about to in reduced revenue testing for COVID-only $XXX For million testing are $XXX our of the now in continued previous and to
Alaris, continue line only to with fiscal related necessity we Regarding model XXXX to shipments demand. medical in
we programs, driving decline gives to on Regarding will revenue, margin that persisting, XXXX. growth, profile. achieving progress in on continue combined Despite in confidence about higher of XXX and has able the improve macro the to inflationary points mitigate levels profitable us focused simplified operating XX% which to continue fiscal earnings, to execution the challenging while margins our expect a absorbing at our least assumptions by margin basis to our COVID-only revenue pressures we with meaningful year be operating make environment
continue internal of improvement containment X% closer come gross expected to to [ph], sales. slight back balance over to SSG&A in and come driven to operating normalize cost our target of by expect leverage. and in We we margin from The improvement the as margin of R&D XX% from is
and assumptions our operating regarding unchanged. remain tax income, other Below interest,
decline double-digit XX to than basis we to headwind before anticipated. to previously growth around about the includes and range is This in a more point about within points absorbing approximately the be testing, expect from X% of XXX continue of currency which We basis a COVID-only anticipated impact XX%. adjusted EPS
of very XX% XX.X% As XX% strong compared to result, anticipated. to a to a implies base growth XX.X% previously earnings low-teens approximately this
the impact Let from me you through now walk estimated currency.
year. Since a against As Based dollar assumes we guidance and $X.XX rates. U.S. all which currencies. but of at major perspective on business using remainder the euro our our of basis, in rates, operational call provide for weakened the manage reminder, current on spot on our November, currency provide current last the the an spot
points XXX purposes, is estimated basis revenues million XXX illustrative currency is prior or approximately on of be year now a view. total to a to which of to approximately basis, our basis points, $XXX about For compared full headwind an company improvement
growth November basis The headwind adjusted of has to compared currency EPS significantly declined basis current points also represent our earnings headwind adjusted growth currency call. to rates, XXX XXX approximately to since approximately a previously. points EPS would At total
by guidance which All in, to approximately prior increasing $XX.X a including to $XX.XX, adjusted estimated are billion midpoint million $XX.X our billion billion be $X.XX to $XX.X billion guidance impact of compared between the an EPS currency, previously we to $XX.XX is our of compared to range $XX.XX are and range $XX.X of to to the reported revenue our increase raising guidance of and at $XX.XX. $XXX
think of various there As fiscal consider. are XXXX to we items phasing,
areas have the slides, more presentation detail note. to outlined in the following but We accompanying key are
margins. regarding First,
We QX impact profitable of margin strong FY most we the to operating grow-over demonstrates the both our of first the be expect COVID-only year. in on year our This to to impact prominent focus margin. be of expect half which revenue, the and XXXX inflation our testing continued of growth similar full given
has to of of As the a year. half profit testing testing was a reminder, weighted the higher margin back COVID-only and COVID-only reinvestment
and progresses prominent to year expansion to simplification through from mitigation to and second inflation benefit and our be the margin continue we we increase the half. As anticipate most programs,
we with Second, the XX% about revenue about impact spot the to regarding in half. XX% over-indexed half headwind be and to year the the first revenue year impact EPS will current first to full expect full the FX. occurring At rates, EPS and of of to
year, with full expect BDX in operating the For to FX the to drop-through line be our earnings margin. we
note. to items timing of couple a Lastly,
percentage in X%. and to normalize as to the of balance remain of over long-term target R&D year expect QX elevated our of the a We sales around
timing predict. is hard XX% effective midpoint year Additionally, guidance year rate occurs discrete over any of best is exact an for throughout as indicates of tax the year, rate the which to balance the evenly the to items the other tax effective full our of assume
reliable, growth as we closing, consistent, to with which planned. pleased durable continuing BD our our XXXX very our demonstrates progress and are profile strategy performance, In
we in look we As are forward with base our in positioned growth guidance, and for well FY our excellent XXXX momentum as reflected business.
let few for turn Tom it additional me that, back With comments. to
